Raffit Hassan, M.D.
National Cancer Institute (NCI)
13
13
4
N/A
0
15
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+24 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (13)
Showing 10 of 13 trials
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
David S Schrump, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Tim F Greten, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
James L Gulley, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Puma
Biotechnology
Shared therapeutic areas:
Dong-Xin Wang, MD, PhD
Peking University First Hospital
Shared therapeutic areas:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
E-mail: ClinicalTrials@ ImClone.com
Eli Lilly and Company
Shared therapeutic areas:
Ajay Goel, PhD
City of Hope Medical Center
Shared therapeutic areas:
Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
Shared therapeutic areas:
Michael B Gill
Power Life Sciences Inc.
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (13)
Showing 13 of 13 trials
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
Amatuximab for High Mesothelin Cancers
SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma
All 13 trials loaded